ATE503743T1 - Kondensierte heteroarylderivate - Google Patents

Kondensierte heteroarylderivate

Info

Publication number
ATE503743T1
ATE503743T1 AT01925981T AT01925981T ATE503743T1 AT E503743 T1 ATE503743 T1 AT E503743T1 AT 01925981 T AT01925981 T AT 01925981T AT 01925981 T AT01925981 T AT 01925981T AT E503743 T1 ATE503743 T1 AT E503743T1
Authority
AT
Austria
Prior art keywords
condensed heteroaryl
heteroaryl derivatives
provides
inhibiting activity
pi3k
Prior art date
Application number
AT01925981T
Other languages
English (en)
Inventor
Masahiko Hayakawa
Hiroyuki Kaizawa
Hiroyuki Moritomo
Ken-Ichi Kawaguchi
Tomonobu Koizumi
Mayumi Yamano
Koyo Matsuda
Minoru Okada
Mitsuaki Ohta
Original Assignee
Astellas Pharma Inc
Ludwig Inst Cancer Res
Imp Cancer Res Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc, Ludwig Inst Cancer Res, Imp Cancer Res Tech filed Critical Astellas Pharma Inc
Application granted granted Critical
Publication of ATE503743T1 publication Critical patent/ATE503743T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT01925981T 2000-04-27 2001-04-26 Kondensierte heteroarylderivate ATE503743T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000128472 2000-04-27
PCT/JP2001/003650 WO2001083456A1 (en) 2000-04-27 2001-04-26 Condensed heteroaryl derivatives

Publications (1)

Publication Number Publication Date
ATE503743T1 true ATE503743T1 (de) 2011-04-15

Family

ID=18637911

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01925981T ATE503743T1 (de) 2000-04-27 2001-04-26 Kondensierte heteroarylderivate

Country Status (10)

Country Link
EP (1) EP1277738B1 (de)
JP (1) JP3649395B2 (de)
KR (1) KR100774855B1 (de)
CN (2) CN100345830C (de)
AT (1) ATE503743T1 (de)
AU (1) AU5261001A (de)
CA (1) CA2407593C (de)
DE (1) DE60144322D1 (de)
ES (1) ES2360933T3 (de)
WO (1) WO2001083456A1 (de)

Families Citing this family (194)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR037641A1 (es) 2001-12-05 2004-11-17 Tularik Inc Moduladores de inflamacion
WO2003070241A1 (en) 2002-02-15 2003-08-28 Rigel Pharmaceuticals, Inc. Inhibitors of tubulin polymerization
DE60325051D1 (de) * 2002-06-06 2009-01-15 Boehringer Ingelheim Pharma SUBSTITUIERTE 3-AMINO-THIENO(2,3-b)PYRIDINE-2-AMIDE UND HERSTELLUNGSVERFAHREN SOWIE DEREN VERWENDUNG
ES2232317B2 (es) * 2002-08-07 2006-04-16 Universidade De Santiago De Compostela Piridopirimidinas sustituidas de formula general i como antiprotozoarios para acuicultura y procedimiento de preparacion.
AU2003255845A1 (en) * 2002-08-22 2004-03-11 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
ATE411996T1 (de) * 2002-09-30 2008-11-15 Bayer Healthcare Ag Kondensierte azolpyrimidinderivate
AU2003258662A1 (en) * 2002-10-02 2004-04-23 Merck Patent Gmbh Use of 4-amino-quinazolines as anti cancer agents
EA013811B1 (ru) 2002-11-21 2010-08-30 Новартис Вэксинес Энд Дайэгностикс, Инк. 2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака
WO2004052373A1 (en) 2002-12-06 2004-06-24 Warner-Lambert Company Llc Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k
CA2510851A1 (en) * 2002-12-20 2004-07-08 Warner-Lambert Company Llc Benzoxazines and derivatives thereof as inhibitors of pi3ks
JP2005104838A (ja) * 2003-01-09 2005-04-21 Tanabe Seiyaku Co Ltd 縮合フラン化合物
CL2004000409A1 (es) 2003-03-03 2005-01-07 Vertex Pharma Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
US7713983B2 (en) 2003-03-03 2010-05-11 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
JP4895806B2 (ja) * 2003-04-09 2012-03-14 エクセリクシス， インク． Ｔｉｅ−２モジュレータと使用方法
GB0313766D0 (en) * 2003-06-13 2003-07-23 Xenova Ltd Pharmaceutical compounds
US20050026944A1 (en) * 2003-07-24 2005-02-03 Patrick Betschmann Thienopyridine and furopyridine kinase inhibitors
AU2004289303A1 (en) * 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Fused heterocyclic compounds
ATE373659T1 (de) * 2004-05-04 2007-10-15 Warner Lambert Co Pyrrolylsubstituierte pyrido(2,3-d)pyrimidin-7- one und derivate davon als therapeutische mittel
GB0415365D0 (en) * 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0415367D0 (en) * 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0415364D0 (en) * 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
MX2007000631A (es) 2004-07-16 2007-03-30 Sunesis Pharmaceuticals Inc Tienopirimidinas utiles como inhibidores de aurora cinasa.
EP1619197A1 (de) * 2004-07-23 2006-01-25 Curacyte Discovery GmbH Substituierte Pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-2,4(1H,3H)dione und -4(3H)one sowie Pyrido[3',2':4,5]furo[3,2-d]-pyrimidin-2,4(1H,3H)dione und -4(3H)one zur Verwendung als Inhibitoren der TNF-alpha Freisetzung
DE502005008916D1 (de) * 2004-07-23 2010-03-11 Medicines Co Leipzig Gmbh Substituierte pyridoä3',2':4,5üthienoä3,2-düpyrimidine und pyridoä3',2':4,5üfuroä3,2-dü-pyrimidine zur verwendung als inhibitoren der pda-4 und/oder tnf-alpha freisetzung
EP1619196A1 (de) * 2004-07-23 2006-01-25 Curacyte Discovery GmbH Substituierte Pyrido[3',2':4,5]thieno[3,2-d]pyrimidine und Pyrido[3',2':4,5]furo[3,2-d]-pyrimidine zur Verwendung als Inhibitoren der PDA-4 und/oder TNF-alpha Freisetzung
WO2006010568A2 (de) * 2004-07-23 2006-02-02 Curacyte Discovery Gmbh Substituierte pyrido [3',2':4,5]thieno[3,2-d]pyrimidin-2,4(1 h,3h)-diones und -4(3h)-one sowie pyrido [3',2' :4,5] furo[3,2-d]pyrimidin -2,4(1 h,3h)-dione und -4(3h)-one zur verwendung als inhibitoren der tnf-allpha freisetzung
US7928107B2 (en) 2004-09-02 2011-04-19 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
NZ553734A (en) * 2004-09-20 2011-01-28 4Sc Ag Novel thiazole derivatives as NF-kappaB inhibitors
US7557112B2 (en) 2004-10-08 2009-07-07 Astellas Pharma Inc. Aromatic-ring-fused pyrimidine derivative
WO2006045010A2 (en) 2004-10-20 2006-04-27 Resverlogix Corp. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
GB0423653D0 (en) * 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
AU2005302448B2 (en) 2004-10-29 2012-07-19 Biocryst Pharmaceuticals, Inc. Therapeutic furopyrimidines and thienopyrimidines
US7875627B2 (en) 2004-12-07 2011-01-25 Abbott Laboratories Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof
GB0428475D0 (en) * 2004-12-30 2005-02-02 4 Aza Bioscience Nv Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
WO2006081659A1 (en) * 2005-02-01 2006-08-10 The University Of British Columbia Meroterpenoid inhibitors of phosphoinositide 3 kinase (pi3k)
GB0508471D0 (en) * 2005-04-26 2005-06-01 Celltech R&D Ltd Therapeutic agents
AU2006261607A1 (en) * 2005-06-24 2006-12-28 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis C.
TW200740820A (en) 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof
ES2281251B1 (es) * 2005-07-27 2008-08-16 Laboratorios Almirall S.A. Nuevos derivados de pirido (3',2':4,5) furo (3,2-d) pirimidina.
US8410109B2 (en) 2005-07-29 2013-04-02 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
US8071597B2 (en) * 2005-08-26 2011-12-06 Merck Serono Sa Pyrazine compounds and uses as PI3K inhibitors
WO2007055773A2 (en) * 2005-08-26 2007-05-18 Novartis Ag Use of inhibitors of pi3k-c2a for the treatment of apoptos i s-related disorders
CN102746298A (zh) * 2005-10-07 2012-10-24 埃克塞里艾克西斯公司 PI3Kα的吡啶并嘧啶酮抑制剂
EA016945B1 (ru) * 2005-10-07 2012-08-30 Экселиксис, Инк. ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
GB2431156A (en) * 2005-10-11 2007-04-18 Piramed Ltd 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
CN101360746B (zh) * 2005-11-22 2013-12-11 库多斯药物有限公司 作为mTOR抑制剂的吡啶并-、吡唑并-和嘧啶并-嘧啶衍生物
JP5161102B2 (ja) * 2005-11-22 2013-03-13 クドス ファーマシューティカルズ リミテッド ｍＴＯＲ阻害剤としてのピリドピリミジン、ピラゾピリミジンおよびピリミドピリミジン誘導体
GB0525081D0 (en) * 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
EP1979325A1 (de) * 2006-01-11 2008-10-15 AstraZeneca AB Morpholinopyrimidinderivate und ihre verwendung in der therapie
GB0616747D0 (en) * 2006-08-24 2006-10-04 Astrazeneca Ab Novel compounds
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
NZ546477A (en) * 2006-04-07 2009-04-30 Auckland Uniservices Ltd 4-Alkylamino-2-(heterocyclic)quinazolines and their use in cancer therapy
WO2007129161A2 (en) 2006-04-26 2007-11-15 F. Hoffmann-La Roche Ag Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor
TW200801012A (en) 2006-04-26 2008-01-01 Piramed Ltd Phosphoinositide 3-kinase inhibitor compounds and methods of use
TWI498332B (zh) 2006-04-26 2015-09-01 Hoffmann La Roche 作為pi3k抑制劑之嘧啶衍生物及相關製備方法、醫藥組合物、用途、套組及產物
KR20090021155A (ko) * 2006-04-26 2009-02-27 에프. 호프만-라 로슈 아게 Ｐｉ3ｋ 억제제로서의 피리미딘 유도체
EP2246354A1 (de) 2006-04-26 2010-11-03 F. Hoffmann-La Roche AG Thieno[3,2-d]Pyrimidin-Derivat geeignet als PI3K Inhibitor
GB0608820D0 (en) 2006-05-04 2006-06-14 Piramed Ltd Pharmaceutical compounds
CA2653654A1 (en) 2006-06-06 2007-12-21 Boehringer Ingelheim International Gmbh Substituted 3-amino-thieno[2,3-b] pyridine-2-carboxamide compounds, their preparation and use
WO2007146284A2 (en) * 2006-06-12 2007-12-21 Vertex Pharmaceuticals Incorporated Thienopyrimidines useful as modulators of ion channels
US8338435B2 (en) 2006-07-20 2012-12-25 Gilead Sciences, Inc. Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections
CA2659851C (en) * 2006-08-23 2014-02-25 Kudos Pharmaceuticals Limited 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
UA96304C2 (en) * 2006-08-23 2011-10-25 Кудос Фармасьютикалз Лимитед 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
AU2007287428B2 (en) 2006-08-24 2011-08-11 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
EP2057129A1 (de) * 2006-08-24 2009-05-13 AstraZeneca AB Für die behandlung proliferativer erkrankungen geeignete morpholinopyrimidinderivate
PT2074122E (pt) 2006-09-15 2011-08-24 Pfizer Prod Inc Compostos de pirido(2,3-d)-pirimidinona e sua utilização como inibidores de pi3
KR20090087027A (ko) * 2006-11-13 2009-08-14 일라이 릴리 앤드 캄파니 염증 질환 및 암의 치료를 위한 티에노피리미디논
MX2009005950A (es) 2006-12-07 2009-10-12 Genentech Inc Compuestos inhibidores de fosfoinositido 3-quinasas y metodos de uso.
RU2470936C2 (ru) 2006-12-07 2012-12-27 Дженентек, Инк. Соединения-ингибиторы фосфоинозитид 3-киназы и способы применения
WO2008075007A1 (en) * 2006-12-21 2008-06-26 Cancer Research Technology Limited Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents
TW200840584A (en) 2006-12-26 2008-10-16 Gilead Sciences Inc Pyrido(3,2-d)pyrimidines useful for treating viral infections
WO2008077650A1 (en) 2006-12-26 2008-07-03 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines useful for treating viral infections
WO2008077649A1 (en) 2006-12-26 2008-07-03 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines useful for treating viral infectons
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
WO2008098058A1 (en) 2007-02-06 2008-08-14 Novartis Ag Pi 3-kinase inhibitors and methods of their use
US20080233127A1 (en) * 2007-03-21 2008-09-25 Wyeth Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
JP2010523639A (ja) * 2007-04-12 2010-07-15 エフ．ホフマン−ラ ロシュ アーゲー 医薬化合物
GB0707087D0 (en) 2007-04-12 2007-05-23 Piramed Ltd Pharmaceutical compounds
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
WO2008152394A1 (en) * 2007-06-12 2008-12-18 F.Hoffmann-La Roche Ag Pharmaceutical compounds
CN101809002B (zh) 2007-07-09 2013-03-27 阿斯利康(瑞典)有限公司 用于与mtor激酶和/或pi3k相关的疾病中的吗啉代嘧啶衍生物
WO2009045174A1 (en) * 2007-10-05 2009-04-09 S*Bio Pte Ltd 2-morpholinylpurines as inhibitors of pi3k
EP2209786B1 (de) * 2007-10-05 2013-02-27 Verastem, Inc. Pyrimidinsubstituierte purinderivate
EA201000484A1 (ru) 2007-10-16 2010-12-30 ВАЙЕТ ЭлЭлСи Тиенопиримидиновые и пиразолопиримидиновые соединения и их применение в качестве ингибиторов киназы mtor и киназы pi3
US20110230464A1 (en) * 2007-10-26 2011-09-22 Paul Goldsmith Purine derivatives useful as p13 kinase inhibitors
GB0721095D0 (en) 2007-10-26 2007-12-05 Piramed Ltd Pharmaceutical compounds
US20090149458A1 (en) * 2007-11-27 2009-06-11 Wyeth PYRROLO[3,2-d]PYRIMIDINE COMPOUNDS AND THEIR USE AS PI3 KINASE AND mTOR KINASE INHIBITORS
AU2008343813B2 (en) * 2007-12-19 2012-04-12 Amgen Inc. Inhibitors of PI3 kinase
CA2712267A1 (en) * 2008-01-15 2009-07-23 Wyeth Llc 3h-[1,2,3]triazolo[4,5-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
US20090192176A1 (en) * 2008-01-30 2009-07-30 Wyeth 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES
CL2009000241A1 (es) * 2008-02-07 2010-09-03 Chugai Pharmaceutical Co Ltd Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer.
CA2721851A1 (en) * 2008-05-30 2009-12-03 Genentech, Inc. Purine pi3k inhibitor compounds and methods of use
KR20110015699A (ko) * 2008-06-11 2011-02-16 제넨테크, 인크. 디아자카르바졸 및 사용 방법
MX2010014230A (es) 2008-06-20 2011-03-29 Astrazeneca Ab Composiciones que contienen pirido [2,3-d] pirimidinas sustituidas con metilmorfolina y proceso relacionado.
SI2346837T1 (sl) 2008-06-26 2015-05-29 Resverlogix Corporation Postopki pripravljanja kinazolinonskih derivatov
US20110105500A1 (en) * 2008-06-27 2011-05-05 S*Bio Pte Ltd. Pyrazine substituted purines
WO2010002954A1 (en) * 2008-07-02 2010-01-07 Wyeth (2-aryl-7h-pyrrolo[2,3-d]pyrimidin-4-yl)morpholine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
CA2729045A1 (en) * 2008-07-31 2010-02-04 Philippe Bergeron Pyrimidine compounds, compositions and methods of use
AR073524A1 (es) 2008-09-30 2010-11-10 Exelixis Inc Piridopirimidinonas inhibidores de pi3k a y m tor
WO2010037765A2 (en) * 2008-10-03 2010-04-08 Merck Serono S.A. 4-morpholino-pyrido[3,2-d]pyrimidines
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
US20100267752A1 (en) * 2008-10-15 2010-10-21 Gilead Palo Alto, Inc. 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
EA024252B1 (ru) 2009-01-08 2016-08-31 Кьюрис, Инк. Ингибиторы фосфоинозитид-3-киназ с цинксвязывающей группой
US8952021B2 (en) 2009-01-08 2015-02-10 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
SI2396307T1 (sl) * 2009-02-11 2015-02-27 Merck Patent Gmbh Novi amino azaheterockliäśni karboksamidi
CN102388041B (zh) 2009-02-12 2014-12-24 默克雪兰诺有限公司 2-吗啉代-吡啶并[3,2-d]嘧啶
KR101913109B1 (ko) 2009-03-18 2018-10-31 리스버로직스 코퍼레이션 신규한 소염제
CN105037364B (zh) * 2009-04-03 2018-04-27 维拉斯通股份有限公司 作为激酶抑制剂的嘧啶取代的嘌呤化合物
WO2010114484A1 (en) * 2009-04-03 2010-10-07 S*Bio Pte Ltd Pyrimidine substituted purine compounds as kinase (s) inhibitors
WO2010120987A1 (en) * 2009-04-17 2010-10-21 Wyeth Llc Ring fused, ureidoaryl- and carbamoylaryl-bridged morpholino-pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
US9757368B2 (en) 2009-04-22 2017-09-12 Resverlogix Corp. Anti-inflammatory agents
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
MX2012002059A (es) * 2009-08-20 2012-04-19 Karus Therapeutics Ltd Compestos heterociclicos triciclicos como inhibidores de fosfoionositida 3-quinasa.
EA021113B1 (ru) 2009-09-03 2015-04-30 Бристол-Майерс Сквибб Кампани Хиназолины в качестве ингибиторов калиевых каналов
CN102020657A (zh) * 2009-09-11 2011-04-20 上海艾力斯医药科技有限公司 稠合杂芳基衍生物、制备方法及其应用
US20130029967A1 (en) * 2009-09-24 2013-01-31 Centro Nacional De Investigaciones Oncologicas (Cnio) Fused Imidazo [3,2 - D] Pyrazines as P13 Kinase Inhibitors
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
EP2499143B1 (de) 2009-11-12 2016-03-16 F.Hoffmann-La Roche Ag N7-substituierte purin und pyrazolopyrimidin verbindungen, zusammensetzungen und verfahren zu ihrer verwendung
BR112012015827A2 (pt) * 2009-12-28 2016-12-06 Dcb Usa Llc novos compostos de pirimidina como inibidores de mtor e p13k
AR079814A1 (es) * 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
EP2528606B1 (de) 2010-01-28 2014-09-24 Alexander Levitzki Auf chinazolin basierende t-zell-proliferationshemmer
UY33221A (es) 2010-02-09 2011-09-30 Univ California MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA
EP2539337A1 (de) * 2010-02-22 2013-01-02 F. Hoffmann-La Roche AG Pyrido-[3,2-d-]pyrimidin-pi3k-delta-hemmer-verbindungen und verfahren zu ihrer verwendung
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
CA2799746C (en) * 2010-05-17 2020-11-24 Sai Reddy Rapid isolation of monoclonal antibodies from animals
CN102268014B (zh) * 2010-06-03 2015-06-03 上海艾力斯医药科技有限公司 一类稠合杂芳基衍生物、制备方法及其应用
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
ES2536780T3 (es) 2010-07-14 2015-05-28 F. Hoffmann-La Roche Ag Compuestos de purina selectivos para I3 p110 delta, y métodos de uso
UA110113C2 (xx) * 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
AU2011282684B2 (en) * 2010-07-29 2015-05-21 Merck Patent Gmbh Cyclic amine azaheterocyclic carboxamides
DK2624695T3 (en) 2010-10-08 2016-01-04 Nivalis Therapeutics Inc NOVEL SUBSTITUTED quinoline-RELATIONS AS S-NITROSOGLUTATHIONREDUKTASEINHIBITORER
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
WO2012058671A1 (en) 2010-10-31 2012-05-03 Endo Pharmaceuticals Inc. Substituted quinazoline and pyrido-pyrimidine derivatives
CN102558185B (zh) * 2010-12-09 2016-02-10 中国科学院上海药物研究所 吡啶并吡咯三嗪化合物、其制备方法和用途
AU2011343518B2 (en) * 2010-12-16 2016-11-10 Nivalis Therapeutics, Inc. Novel substituted bicyclic aromatic compounds as S-nitrosoglutathione reductase inhibitors
TW201500358A (zh) 2010-12-16 2015-01-01 赫夫門羅氏藥廠股份有限公司 三環ｐｉ３ｋ抑制劑化合物及其使用方法
US8791107B2 (en) * 2011-02-25 2014-07-29 Takeda Pharmaceutical Company Limited N-substituted oxazinopteridines and oxazinopteridinones
WO2012131297A1 (en) 2011-03-28 2012-10-04 Jonathan Bayldon Baell Pyrido [3',2' :4,5] thieno [3, 2-d] pyrimidin- 4 - ylamine derivatives and their therapeutical use
WO2012135571A1 (en) 2011-04-01 2012-10-04 Curis, Inc. Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
CN102731525A (zh) * 2011-04-08 2012-10-17 上海艾力斯医药科技有限公司 苯并吗啉衍生物
KR101106778B1 (ko) * 2011-05-24 2012-01-18 한국바이오시스템(주) 공공시설 및 공동주택용 자연정화형 하폐수·빗물처리시설과 이를 이용한 하폐수·빗물처리방법 및 물순환 시스템
BR112014007310A2 (pt) 2011-09-27 2017-04-04 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante
CA2851996C (en) 2011-11-01 2020-01-07 Resverlogix Corp. Pharmaceutical compositions for substituted quinazolinones
WO2013078126A1 (en) 2011-11-23 2013-05-30 Cancer Research Technology Limited Thienopyrimidine inhibitors of atypical protein kinase c
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
UA115544C2 (uk) 2012-03-13 2017-11-27 Респіверт Лімітед Спосіб підвищення стабільності до хімічного розкладання фармацевтичної композиції та застосування стабілізуючого агента у фармацевтичній коипозиції
US9145411B2 (en) 2012-08-02 2015-09-29 Asana Biosciences, Llc Substituted amino-pyrimidine derivatives
IN2015DN03235A (de) 2012-11-07 2015-10-02 Karus Therapeutics Ltd
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
JP2016507496A (ja) 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． ブロモドメイン阻害剤としての新規複素環式化合物
JP6387360B2 (ja) 2013-03-14 2018-09-05 ノバルティス アーゲー 変異ｉｄｈの阻害薬としての３−ピリミジン−４−イル−オキサゾリジン−２−オン
TW201522341A (zh) 2013-03-15 2015-06-16 Respivert Ltd 化合物
US9227977B2 (en) 2013-03-15 2016-01-05 Respivert Ltd. Phosphoinositide 3-kinase inhibitors
PT2994465T (pt) 2013-05-10 2018-10-25 Karus Therapeutics Ltd Novos inibidores de histona desacetilase
CN104557872B (zh) * 2013-10-16 2017-05-24 上海璎黎药业有限公司 稠合杂环化合物、其制备方法、药物组合物和用途
CN103664876B (zh) * 2013-11-01 2016-04-20 苏州东南药业股份有限公司 喹啉类衍生物及其用途
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
CN104311494A (zh) * 2014-10-16 2015-01-28 西安交通大学 间-(4-吗啉基-2-喹唑啉基)苯甲酰胺类化合物及其合成方法和应用
GB201419228D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
GB201419264D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
US10111885B2 (en) 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
KR101845931B1 (ko) 2015-06-18 2018-04-05 한국화학연구원 헤테로아릴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 pi3 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
GB201514751D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514754D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
CN105153190B (zh) * 2015-08-21 2017-07-21 江西科技师范大学 含联芳基酰胺结构的杂环并嘧啶类化合物及其制备方法和应用
WO2017044766A1 (en) 2015-09-10 2017-03-16 Nivalis Therapeutics, Inc. Solid forms of an s-nitrosoglutathione reductase inhibitor
EP3380476B1 (de) 2015-11-23 2020-09-30 Council of Scientific and Industrial Research Kondensierte pyrimidine als isoformselektive phosphoinositid-3-kinase-alpha-inhibitoren und verfahren zur herstellung davon
SG11201804901WA (en) 2015-12-22 2018-07-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
WO2017184547A1 (en) 2016-04-18 2017-10-26 New York University Quinoline compounds as modulators of rage activity and uses thereof
EA201992780A1 (ru) 2017-06-21 2020-06-02 ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания
CN109384782A (zh) * 2017-08-04 2019-02-26 厦门大学 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途
CN107805255B (zh) * 2017-09-22 2020-06-16 中国药科大学 呋喃[3，2-b]吡啶-2(1H)-酮类化合物、制备方法和医药用途
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
KR20210039368A (ko) 2018-07-26 2021-04-09 도메인 테라퓨틱스 치환된 퀴나졸리논 유도체 및 mGluR4의 양성 알로스테릭 조절인자로서의 이의 용도
CN113164466B (zh) 2018-09-11 2025-07-08 柯瑞斯公司 使用具有锌结合部分的磷酸肌醇3-激酶抑制剂的联合治疗
US12054488B2 (en) 2018-09-27 2024-08-06 Suzhou Raymon Pharmaceuticals Company, Ltd. Pyrazolopyrimidine compound and preparation method therefor and use thereof in preparation of anti-cancer drug
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
US12391705B2 (en) 2018-12-19 2025-08-19 Shy Therapeutics, Llc Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
KR20210124310A (ko) 2019-02-06 2021-10-14 벤테라, 인코포레이티드 국소 포스포이노시티드 3-키나제 억제제
CN109796415B (zh) * 2019-03-29 2020-10-30 武汉德诺美生物医药股份有限公司 Egfr抑制剂及其应用
KR102338609B1 (ko) 2019-05-20 2021-12-14 보령제약 주식회사 피리도-피리미딘 화합물 및 이를 유효성분으로 포함하는 pi3k 관련 질환의 예방 또는 치료용 약학적 조성물
GB201909468D0 (en) 2019-07-01 2019-08-14 Karus Therapeutics Ltd Compounds for treating cancer
TW202134245A (zh) * 2019-12-05 2021-09-16 美商邊際分析公司 稠合三環雜環化合物及其用途
CN113072543B (zh) * 2020-01-03 2022-07-22 南方医科大学 一种2-芳杂环基喹唑啉酮类化合物及其制备方法和用途
TWI885039B (zh) 2020-01-13 2025-06-01 美商邊際分析公司 經取代吡唑并嘧啶及其用途
CN115968369B (zh) 2020-06-30 2026-04-28 株式会社保宁 作为pi3k抑制剂的化合物的制备方法及用于制备其的中间体化合物
EP4192431A1 (de) * 2020-08-04 2023-06-14 Venthera, Inc. Formulierungen von phosphoinositid-3-kinase-hemmern
TW202237095A (zh) * 2020-12-03 2022-10-01 德商艾斯巴赫生物有限公司 Ａｌｃ１抑制劑及與ｐａｒｐｉ之協同性
CN115991716B (zh) * 2021-10-19 2025-10-17 中国药科大学 嘧啶并环类化合物及其衍生物、制备方法、药物组合物和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3808211A (en) * 1972-06-12 1974-04-30 Morton Norwich Products Inc 4-(substituted amino)-2-(5-nitro-2-furyl)pyrimido(4,5-d)pyrimidines
CH612432A5 (de) 1975-05-12 1979-07-31 Sandoz Ag
JPS56120768A (en) 1980-01-31 1981-09-22 Ciba Geigy Ag Color developing quinazoline compound
JPS58172379A (ja) * 1982-04-02 1983-10-11 Showa Denko Kk 新規なキナゾリン誘導体
US4560692A (en) 1984-07-18 1985-12-24 Hoffmann-La Roche Inc. 4-Piperidino-2-phenylquinolines
JPH02129169A (ja) 1988-11-08 1990-05-17 Ube Ind Ltd キノリン化合物およびその医薬用途
US5304554A (en) 1990-04-27 1994-04-19 Emory University 4-[(alkyl or dialkyl)amino]quinolines and their method of preparation
WO1995000524A1 (fr) * 1993-06-17 1995-01-05 Otsuka Pharmaceutical Factory, Inc. Derive de diester phosphonique
GB2295387A (en) * 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
JPH1087492A (ja) * 1996-06-25 1998-04-07 Ono Pharmaceut Co Ltd 一酸化窒素産生阻害剤
EP0882717B1 (de) * 1996-10-01 2010-09-08 Kyowa Hakko Kirin Co., Ltd. Stickstoff enthaltende heterocyclische verbindungen
JPH10175977A (ja) * 1996-12-13 1998-06-30 Takeda Chem Ind Ltd 縮合インドール誘導体、その製造法及び用途
JPH11209287A (ja) * 1998-01-23 1999-08-03 Ono Pharmaceut Co Ltd 一酸化窒素産生阻害剤
EP1067123B1 (de) * 1998-03-31 2011-01-19 Kyowa Hakko Kirin Co., Ltd. Stickstoffenthaltende heterocyclische verbindungen
US5990117A (en) * 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives

Also Published As

Publication number Publication date
KR20020093086A (ko) 2002-12-12
CA2407593C (en) 2011-01-11
EP1277738B1 (de) 2011-03-30
EP1277738A4 (de) 2005-02-09
DE60144322D1 (de) 2011-05-12
CN100345830C (zh) 2007-10-31
CA2407593A1 (en) 2001-11-08
EP1277738A1 (de) 2003-01-22
CN1629145A (zh) 2005-06-22
ES2360933T3 (es) 2011-06-10
AU5261001A (en) 2001-11-12
JP3649395B2 (ja) 2005-05-18
WO2001083456A1 (en) 2001-11-08
CN1426398A (zh) 2003-06-25
KR100774855B1 (ko) 2007-11-08
CN1186324C (zh) 2005-01-26

Similar Documents

Publication Publication Date Title
DE60144322D1 (de) Kondensierte heteroarylderivate
DK1277754T3 (da) Imidazopyridinderivater
ATE215954T1 (de) Pyrazolo(4,3-d)pyrimidin-derivate und diese enthaltende pharmazeutische zubereitungen
IL160915A0 (en) Indolizines inhibiting kinase proteins
DE60204452D1 (de) Pyrazolo[1,5]pyridinderivate
EP1622616A4 (de) Hemmer der akt aktivität
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
DE69428025D1 (de) Proteinkinase C-Inhibitoren
DE69908819D1 (de) Glycopeptid-derivate und pharmazeutische zusammensetzungen, die sie enthalten
ATE350036T1 (de) Tetrahydroquinolin-derivate
MA26819A1 (fr) Pteridinones servant d' inhibiteurs de kinases.
WO2001019829A3 (en) Pyrazolopyrimidines as therapeutic agents
UA83091C2 (en) Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors
PL359563A1 (pl) Związki pirolo [2,3-d] pirymidynowe jako środki immunosupresyjne
BR0016878A (pt) Inibidores tricìclicos de cinases protéicas
ATE321038T1 (de) Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren
ES2243579T3 (es) Derivados de pirazolopirideno.
CA2461622A1 (en) Substituted benzimidazole compounds and their use for the treatment of cancer
IL151200A0 (en) Tricyclic imidazopyridine prodrug derivatives and pharmaceutical compositions containing the same
MY136297A (en) Piperazine derivatives having sst1 antagonistic activity
DE69911785D1 (de) Triazolo[4,5-d]pyrimidin-verbindungen
ATE274515T1 (de) Pyrazolopyridinderivate
MY129094A (en) Condensed polycyclic compounds
ATE325116T1 (de) Farnesyltransferasehemmende 4- heterocyclylchinolin- und chinazolinderivate
ATE272642T1 (de) Thieno(2,3-d)pyrimidindione und ihre verwendung als pharmazeutische mittel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties